Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be diagnosed with AOSD according to preliminary classification by Yamaguchi (1992).~* Other diseases with similar symptoms must be excluded. Has been exposed to a corticosteroid for ≥2 months prior to randomization for AOSD.~* Needs a prednisolone dose ≥10 mg/day or equivalent, yet unacceptable disease activity determined by the investigator.~* Anti-TNF agents must be discontinued 4 to 8 weeks prior to commencing study medication.~Exclusion Criteria:~* Use of corticosteroids (prednisolone equivalent \<10 mg/day.~* History of recurrent or chronic infection, including:~  * tuberculosis~ * any malignancy~ * any other major chronic inflammatory disease syndrome~ * drug or alcohol abuse~ * known positivity for hepatitis B, C or HIV.~* Use of anti-TNF agents during ≤4 weeks (etanercept) or≤8 weeks (infliximab or adalimumab) prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): experimental drug of study
- comparator (Type: ACTIVE_COMPARATOR): comparators:methotrexate, azathioprine, leflunomide or supfasalazine

Based on this trial design, predict the completion outcome and termination type (if applicable).